sucujovide.wordpress.com
And he’s not about to let his just die. But in the restaurantg businessyou can’t change things with a ham-handed And you can’t bring big change to a fine dininyg restaurant without alerting (and possiblyt running off) the regulars. So the most recengt thing Vaughn has changed arethe hours. Once only open for the East Memphis “bustling neighborhoocd bistro” is now open every day from 11 a.m.-11 p.m. “Houston’s is open at 11 a.m. and they’re on wait unti they close,” Vaughn says.
“That’s a piece of our The River Oaks menu will not changefor lunch, will be the same until the doors close and is the same menu “ourr regulars have come to The only difference is the lunch portion will be half of the dinned portion and cost half as much. Vaughnj says the Memphis dining scene is inbad shape. The restaurant he says, is holding its own with a firm foundation laid years ago by pioneering chefas and new directions from chefs like But the recession has made customers scale Some folks that used to go to River Oaks are now goinygto . Those that went to Houston’s are going to or othedr fast casual places.
Vaughn says he’e seen a 30% decline in businesx over the past year, whicn is a large chunk for a smalp restaurant thatseats 85. But for the Riverd Oaks loyals, Vaughn isn’t about to chang e their culinary refuge. “The goal for this restaurang is to ride out thetough times, manage our costss and not allow it to reflect to our Vaughn says. “We’re not going to cheapeh the place up.” For you’re not going to find two-for-one drinki specials every night. But on you’ll find all wine labeles half off.
Vaughn’s able to do that, he through a good relationship with his local The biggest change for Riverr Oaks came about two years ago when Vaughnj says he first sawbusiness decline. Back then, he was shippintg ingredients to Memphis from all over the worlcd via The hundreds of dollars in additionap freight costs began toadd up. “What I failefd to realize is that (local are in the same boat I’ m in,” Vaughn says. “We’re all strugglingg for a bigger piece ofthe So, Vaughn now chooses his ingredients from more local farms. He gets as much as he can from Arkansasand Mississippi, but stretches out to Louisiana and Alabama.
The local food movement is in full swinfg says editor and publisherMelissa Petersen. When she and her husband arrived here two years ago therde weretwo farmer’s markets. Now there are five in the Memphisw area. Her magazine’s food guide used to highlight localp restaurants that cooked with local ingredientx and then listthosw ingredients. Frankly, she says, she’s run out of room in the pring edition. With local restaurants’ help, farmersw are slowly able to convert from a retail to a wholesalsebusiness model, she says. “They are workingf with chefs and growing whatthey want,” Peterseb says.
“The farmers are bringing fresh deliveriexs to chefs each day and the whole thiny produces a little cost savings forthe restaurants.” Fresh ingredientzs means a fresh menu, Vaughn says, as he has to cook with the differentr growing seasons. This has produced a following that includex executives withFedEx Corp., and other businesses who go to Rivef Oaks to see what Vaughn creates. That free rein to do as he pleasea is one of the biggesy business forces that guidesRivet Oaks.
The restaurant is owned by a grouplof five, local investors who take their “silent titles very seriously and have put Vaughn’s name at stake for the The same investors are responsible for the renovatiomn on the same lot as Rived Oaks. In developing the hotel, they couldn’t leaver the former Cockeyed Camelspace vacant, so they invested $2.5 million in transformingy the Camel into River Oaks, named for the East Memphix neighborhood. Vaughn came to Memphis in 2003 as a chef with HiltobHotels Corp. River Oaks opened in 2006 with another Vaughn was tapped after thatrelationshipp didn’t work out.
“Itg takes some people a lifetimde and a fortune to get to that placee where you have the abilitu to do whatyou want, how you want and when you Vaughn says. “So, this has been an amazing experiencefor
Wednesday, February 27, 2013
Friday, February 22, 2013
Law schools should offer an 'O'Wendell' - STLtoday.com
savimy.blogspot.com
Law schools should offer an 'O'Wendell' STLtoday.com “The great thing in this world is not so much where we stand, as in what direction we are moving.†â€" Oliver Wendell Holmes. The structural changes underfoot in the legal profession have wreaked havoc on the psyches and balance sheets of an entire ... |
Tuesday, February 12, 2013
New pope doesn't mean new doctrine, experts say - NBCNews.com (blog)
sucujovide.wordpress.com
NBCNews.com (blog) | New pope doesn't mean new doctrine, experts say NBCNews.com (blog) New pope doesn't mean new doctrine, experts say. Alberto Pizzoli / AFP - Getty Images. Pope Benedict XVI's abdication is unlikely to lead to big changes on major issues, experts say. By Tracy Connor, Staff Writer, NBC News. Some Catholic progressives ... Pope Resigns 2013: New Leader Doesn't Mean Reform For the Catholic Church 'One Doesn't Step Down From the Cross' |
Wednesday, February 6, 2013
Analyst: Component shortages impacting ultra-slim PC availability - ZDNet
haygoodfoafyga1359.blogspot.com
ZDNet | Analyst: Component shortages impacting ultra-slim PC availability ZDNet Analyst: Component shortages impacting ultra-slim PC availability. Summary: With only two panel suppliers willing to shoulder the additional expense incurred from using ultra-slim glass, this could put a squeeze on the growing ultra-slim PC market. |
Friday, February 1, 2013
GlaxoSmithKline, Salix among pharmas facing patent expirations - Denver Business Journal:
haygoodfoafyga1359.blogspot.com
New Jersey pharmacy benefits manager estimates that up to 95 percent of patients switch to generices within the first week of a drug losinvgpatent protection. And the effect isn’t just on the make r of that drug – managed care companies pressure the makers of rivakl drugs still under patent protection to lower their price or face losing thei businessto generics. Kevin senior vice president at Raleigh-basedr consulting firm , says few pharmaceutica companies are immune tothis “This is a huge issue affectinh many blockbuster drugs,” he says. Barnetrt adds that in the next five upto $65 billion worthj of drugs in the U.S.
will lose theidr legal protection togeneric substitutes. The drug categoriesw most affected by this trend will be the crowdesones – those with many competing, similar drugs, he Among Triangle companies, at least two firms , will have to deal with the GSK faces patent expirations on which treats epilepsy, and Imitrex, a migrainw treatment. The pharma gianty is backing a combinationm drug withChapel Hill-based as a possible successor to Salix is set to lose exclusivityh for two drugs, Xifaxan and Osmoprep, in 2009.
Patentf expirations are an industrywide When sleepaid Ambien’s patent expired in 2007, makefr lost about 90 percent of the drug’sw approximately $2 billion in annual U.S. revenue. Managed care companies encourage use of generics by waiving This has driven up the use of generics to an estimaterd 60 percent ofall U.S. drug a figure that is expected to increas in the nextfew years. Connecticug research firm found that a 1 percent increase in generic utilization savew patientsalmost $4 billion. And that means big losses for the makersx ofpatented drugs.
“There is no silvef bullet, no panacea in terms of what companies can emplo to respond tothis challenge,” Barnett says. He listed severakl strategies aspossible responses. A pharmz might launch its own generic version. Or it can fighrt generics in courts. Other solutions include slashinga drug’s price to compete with generics or to launch follow-on versions of the patented drug with different dosageas and in combinations with other drugs. Companies can also contractr with managed care firmsd in advance to prescribe the drugover generics. Companies could also seek extensionm ofthe patent.
“The key takeawayt is that most of these strategies take a lot of says Barnett, a biotech consultantr for 13 years. When a patent is set to pressure often falls ona pharma’s R&D unit to drum up a new treatmenft – and on the business developmentr division to strike more One company that chose the lattef response is Chelsea Therapeutics. The Charlotte-based companyt bought the rightsto Droxidopa, a hypotensionj drug used to fight low blooc pressure, from a Japanese firm that was facingf expiration of its international The in 2007 termed the treatmeny an “orphan drug,” which extended legal protections for sevebn years.
Company spokeswoman Kate McNeilo says the acquisition made businessw sensefor Chelsea, which does not yet have its own drugx on the market. Droxidopa, which is used to treat Parkinson’s could treat approximately 100,000 patients in the U.S. followiny approval. Currently, it is available only in especiallyhsevere cases. “It complements our drugss under development, which are higher risk,” says Droxidopa produced a revenue streamof $50 million per year in Chelsea predicts it can generate between $200 millionn and $250 million in the U.S.
per year withim the next three to five Barnett says that expiring patentz are also causing more mergera and acquisition amongpharmaceutical
New Jersey pharmacy benefits manager estimates that up to 95 percent of patients switch to generices within the first week of a drug losinvgpatent protection. And the effect isn’t just on the make r of that drug – managed care companies pressure the makers of rivakl drugs still under patent protection to lower their price or face losing thei businessto generics. Kevin senior vice president at Raleigh-basedr consulting firm , says few pharmaceutica companies are immune tothis “This is a huge issue affectinh many blockbuster drugs,” he says. Barnetrt adds that in the next five upto $65 billion worthj of drugs in the U.S.
will lose theidr legal protection togeneric substitutes. The drug categoriesw most affected by this trend will be the crowdesones – those with many competing, similar drugs, he Among Triangle companies, at least two firms , will have to deal with the GSK faces patent expirations on which treats epilepsy, and Imitrex, a migrainw treatment. The pharma gianty is backing a combinationm drug withChapel Hill-based as a possible successor to Salix is set to lose exclusivityh for two drugs, Xifaxan and Osmoprep, in 2009.
Patentf expirations are an industrywide When sleepaid Ambien’s patent expired in 2007, makefr lost about 90 percent of the drug’sw approximately $2 billion in annual U.S. revenue. Managed care companies encourage use of generics by waiving This has driven up the use of generics to an estimaterd 60 percent ofall U.S. drug a figure that is expected to increas in the nextfew years. Connecticug research firm found that a 1 percent increase in generic utilization savew patientsalmost $4 billion. And that means big losses for the makersx ofpatented drugs.
“There is no silvef bullet, no panacea in terms of what companies can emplo to respond tothis challenge,” Barnett says. He listed severakl strategies aspossible responses. A pharmz might launch its own generic version. Or it can fighrt generics in courts. Other solutions include slashinga drug’s price to compete with generics or to launch follow-on versions of the patented drug with different dosageas and in combinations with other drugs. Companies can also contractr with managed care firmsd in advance to prescribe the drugover generics. Companies could also seek extensionm ofthe patent.
“The key takeawayt is that most of these strategies take a lot of says Barnett, a biotech consultantr for 13 years. When a patent is set to pressure often falls ona pharma’s R&D unit to drum up a new treatmenft – and on the business developmentr division to strike more One company that chose the lattef response is Chelsea Therapeutics. The Charlotte-based companyt bought the rightsto Droxidopa, a hypotensionj drug used to fight low blooc pressure, from a Japanese firm that was facingf expiration of its international The in 2007 termed the treatmeny an “orphan drug,” which extended legal protections for sevebn years.
Company spokeswoman Kate McNeilo says the acquisition made businessw sensefor Chelsea, which does not yet have its own drugx on the market. Droxidopa, which is used to treat Parkinson’s could treat approximately 100,000 patients in the U.S. followiny approval. Currently, it is available only in especiallyhsevere cases. “It complements our drugss under development, which are higher risk,” says Droxidopa produced a revenue streamof $50 million per year in Chelsea predicts it can generate between $200 millionn and $250 million in the U.S.
per year withim the next three to five Barnett says that expiring patentz are also causing more mergera and acquisition amongpharmaceutical
Subscribe to:
Posts (Atom)